Press Release

CAMARILLO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that company management will be presenting a corporate overview and participating in one-on-one meetings at the Biocom California Global Life Science Partnering Conference in …

Dyve Biosciences to Present at the Biocom California Global Life Science Partnering Conference Read More »

CAMARILLO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced that company management will be presenting a corporate overview and participating in 1-on-1 meetings at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually …

Dyve Biosciences to Present at the 32nd Annual Oppenheimer Healthcare Conference Read More »

Synergestic collaboration will evaluate DYVE’s buffering candidate delivered transdermally for future clinical oncology applications CAMARILLO, Calif. and TAMPA, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a broad pipeline of clinical assets, today announced a joint, two-year research collaboration with Moffitt Cancer …

Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center Read More »

Two key opinion leaders will discuss gout treatment landscape and perspectives on Phase 2 TARGETS study of DYV702 for the treatment of pain associated with acute gout flares Webinar to be held Tuesday, November 23rd @ 11am ET THOUSAND OAKS, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology …

Dyve Biosciences Hosting Key Opinion Leader Webinar on Gout and DYV702 Read More »

THOUSAND OAKS, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical stage biotechnology company, today announced that Camilla V. Simpson has joined Dyve’s Board of Directors. Ryan Beal, M.D., Chief Executive Officer of Dyve, stated: “We are delighted to have Camilla join our board during this exciting time for Dyve. Our lead …

Dyve Biosciences appoints Camilla V. Simpson to its board Read More »

THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. today announced that longtime Pfizer Executive Chuck Harbert, Ph.D. has joined the company in the role of Chief Scientific Officer. Dr. Harbert is an acclaimed medicinal chemist and pharmaceutical industry executive with accomplishments spanning three decades with Pfizer. Dr. Harbert held a variety of leadership roles across the drug …

Dyve Biosciences Announces Chuck Harbert, Ph.D. to Join as Chief Scientific Officer Read More »

THOUSAND OAKS, Ca.–(BUSINESS WIRE)–Dyve Biosciences, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2 trial of DYV-700, the company’s topically administered therapeutic being developed to reduce the pain and duration of an acute gout flare. Dyve intends to initiate the Phase 2 trial, …

Dyve Biosciences Receives FDA Clearance to Begin Phase 2 Study of DYV-700 for Treatment of Acute Gout Pain Read More »